Trial Profile

Nivolumab Plus Stereotactic Body Radiotherapy (SBRT) in II and III Line of Patients With Metastatic Renal Cell Carcinoma (mRCC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms NIVES

Most Recent Events

29 Aug 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Results of exploratory analysis the correlation between PD-L1 expression and clinical outcomes, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
29 Jul 2020 Planned End Date changed from 14 Jul 2020 to 14 Jul 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com